Fludrocortisone acetate

CLINICAL USE

Replacement therapy in adrenal insufficiency

DOSE IN NORMAL RENAL FUNCTION

50–300 micrograms daily

PHARMACOKINETICS

Molecular weight :422.5

%Protein binding :70–80

%Excreted unchanged in urine : 80% (as metabolites)

Volume of distribution (L/kg) :Widely distributed

half-life – normal/ESRD (hrs) :3.5 (Biological half-life 18–36 hours)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin

Anticoagulants: efficacy of coumarins may be altered

Anti-epileptics: metabolism accelerated by carbamazepine, barbiturates, phenytoin and primidone

Antifungals: increased risk of hypokalaemia with amphotericin – avoid concomitant use; metabolism possibly inhibited by itraconazole and ketoconazole

Antivirals: concentration possibly increased by ritonavirCytotoxics: increased risk of haematological toxicity with methotrexateVaccines: high dose corticosteroids can impair immune response to vaccines – avoid concomitant use with live vaccines

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Use for as short a time and as low a dose as possible

Tags: post-by-auto-php